HF
RVPHW

HRT Financial’s Reviva Pharmaceuticals Warrants RVPHW Stock Holding History

HRT Financial’s Portfolio RVPHW Stock Details RVPHW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-121,576
Closed -$55K – 3440
2021
Q1 		$55K Sell
121,576
-11,048
-8% -$7.12K ﹤0.01% 2532
2020
Q4 		$89K Hold
132,624
– – ﹤0.01% 1648
2020
Q3 		$70K Buy
132,624
+82,224
+163% +$36.7K ﹤0.01% 1610
2020
Q2 		$23K Buy
+50,400
New +$11.8K ﹤0.01% 1406

Other funds holding RVPHW

BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

HRT Financial's RVPHW Position: Q2 2021 in Review

HRT Financial sold out of Reviva Pharmaceuticals Warrants (RVPHW) in Q2 2021, closing a stake of 121,576 shares — an estimated $55K sold.

HRT Financial first reported a position in RVPHW in Q2 2020 and held it in 4 quarters. The position peaked at $89K in Q4 2020. 10 funds tracked by Wall St. Rank hold RVPHW as of Q2 2021.

  • HRT Financial reported no remaining Reviva Pharmaceuticals Warrants position as of Q2 2021 after selling out during the quarter.
  • HRT Financial sold 121,576 Reviva Pharmaceuticals Warrants shares in Q2 2021, an estimated $55K.
  • HRT Financial first reported a position in Reviva Pharmaceuticals Warrants in Q2 2020 and held it in 4 quarters.
  • HRT Financial's Reviva Pharmaceuticals Warrants position peaked at $89K in Q4 2020.
  • 10 funds tracked by Wall St. Rank held Reviva Pharmaceuticals Warrants as of Q2 2021.

Based on HRT Financial's 13F filing for Q2 2021, filed 16 Aug 2021.